Drug tolerance in Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 11, 1999, Pages 2600-2606

  Wallis, Robert S ^a,i   Patil, Shripad ^b   Cheon, Seon Hee ^a,c   Edmonds, Kay ^a   Phillips, Manijeh ^a   Perkins, Mark D ^d,e,j   Joloba, Moses ^f   Namale, Alice ^f   Johnson, John L ^a   Teixeira, Lucileia ^d   Dietze, Reynaldo ^d   Siddiqi, Salman ^g   Mugerwa, Roy D ^f   Eisenach, Kathleen ^h   Ellner, Jerrold J ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^c Ewha Womans University   (South Korea)

^d Federal Institute of Espirito Santo   (Brazil)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f MAKERERE UNIVERSITY   (Uganda)

^g BD Technologies   (United States)

^h UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

ⁱ CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j Communic Dis Cluster World H ^*  (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN;

ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CLINICAL ARTICLE; DRUG TOLERANCE; HUMAN; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

EID: 0032758085     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.11.2600     Document Type: Article

References (24)

1. Aber, V. R., and A. J. Nunn. 1978. Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy. Bull. Int. Union Tuberc. 53:275-280.
2. Anonymous. 1984. A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 60 months. Am. Rev. Respir. Dis. 130:23-28.
3. Anonymous. 1989. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am. Rev. Respir. Dis. 139:871-876.
4. Balasubramanian, R., S. Sivasubramanian, V. K. Vijayan, R. Ramachandran, M. S. Jawahar, C. N. Paramasivan, N. Selvakumar, and P. R. Somasandaram. 1990. Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India. Tubercle 71:253-258.
5. Bishal, W. R., and R. E. Chaisson. 1997. Short-course chemoprophylaxis for tuberculosis. Clin. Chest Med. 18:115-122.
6. Botha, F. J., F. A. Sirgel, D. P. Parkin, W. B. van-de, P. R. Donald, and D. A. Mitchison. 1996. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. S. Afr. Med. J. 86:155-158.
7. Centers for Disease Control and Prevention. 1998. Use of short-course tuberculosis preventive therapy regimens in HIV-seronegative persons. JAMA 280:1736.
8. Epstein, M. D., N. W. Schluger, A. L. Davidow, S. B. Bonk, W. N. Rom, and B. Hanna. 1997. Time to detection of M. tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest 113:379-386.
9. Felten, M. K. 1989. Importance of rifampicin in combined daily/intermittent chemotherapy for tuberculosis. S. Afr. Med. J. 75:524-526.
10. Halsey, N. A., J. S. Coberly, J. Desormeaux, P. Losikoff, J. Atkinson, L. H. Moulton, M. Contave, M. Johnson, H. Davis, C. Geiter, et al. 1998. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 351:786-792.
11. Heifets, L., and P. Lindholm-Levy. 1992. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am. Rev. Respir. Dis. 145:1223-1225.
12. Herbert, D., C. N. Paramasivan, P. Venkatesan, G. Kubendiran, R. Prabhakar, and D. A. Mitchison. 1996. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 40:2296-2299.
13. Kim, K. S., and A. S. Bayer. 1987. Significance of in-vitro penicillin tolerance in experimental enterococcal endocarditis. J. Antimicrob. Chemother. 19: 475-485.
14. Mehrotra, M. L., K. D. Gautam, and C. K. Chaube. 1984. Shortest possible acceptable effective chemotherapy in ambulatory patients with pulmonary tuberculosis. Part II. Results during the 24 months after the end of chemotherapy. Am. Rev. Respir. Dis. 129:1016-1017.
15. Mikusova, K., R. A. Slayden, G. S. Besra, and P. J. Brennan. 1995. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob. Agents Chemother. 39:2484-2489.
16. Mitchison, D. A. 1985. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66:219-225.
17. Mitchison, D. A. 1993. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am. Rev. Respir. Dis. 147: 1062-1063. (Letter.)
18. Mitchison, D. A., and A. J. Nunn. 1986. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am. Rev. Respir. Dis. 133:423-430.
19. Tuomanen, E. 1986. Phenotypic tolerance: the search for beta-lactam antibiotics that kill nongrowing bacteria. Rev. Infect. Dis. 8(Suppl. 3):S279-S291.
20. Villarino, M. E., R. Ridzon, P. C. Weismuller, M. Elcock, R. M. Maxwell, J. Meador, P. J. Smith, M. L. Carson, and L. J. Getter. 1997. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am. J. Respir. Crit. Care Med. 155:1735-1738.
21. Wallis, R. S., M. Perkins, M. Phillips, M. Joloba, B. Demchuk, A. Namale, J. C. Johnson, D. Williams, K. Wolski, L. Teixeira, et al. 1998. Induction of the antigen 85 complex of M. tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis. J. Infect. Dis. 178:1115-1121.
22. Yajko, D. M., J. J. Madej, M. V. Lancaster, C. A. Sanders, V. L. Cawthon, B. Gee, A. Babst, and W. K. Hadley. 1995. Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. J. Clin. Microbiol. 33:2324-2327.
23. Yajko, D. M., C. Wagner, V. J. Tevere, T. Kocagoz, W. K. Hadley, and H. F. Chambers. 1995. Quantitative culture of Mycobacterium tuberculosis from clinical sputum specimens and dilution endpoint of its detection by the Amplicor PCR assay. J. Clin. Microbiol. 33:1944-1947.
24. Yamori, S., S. Ichiyama, K. Shimokata, and M. Tsukamura. 1992. Bacteriostatic and bactericidal activity of antituberculosis drugs against Mycobacterium tuberculosis, Mycobacterium avium-Mycobacterium intracellulare complex and Mycobacterium kansasii in different growth phases. Microbiol. Immunol. 36:361-368.